Mia's Feed
Medical News & Research

Impact of Including Anxiety as a Qualifying Condition in Medical Cannabis Programs

Impact of Including Anxiety as a Qualifying Condition in Medical Cannabis Programs

Share this article

A recent study highlights how adding anxiety as a qualifying condition in Pennsylvania's medical cannabis program has significantly shifted diagnosis patterns, raising questions about effectiveness and policy implications.

2 min read

Recent research from the University of Pittsburgh and Johns Hopkins University has revealed significant changes in Pennsylvania's medical cannabis program following the addition of anxiety disorders as a qualifying condition. Just months after this inclusion, anxiety quickly rose to be the leading diagnosis for cannabis certifications, highlighting a notable shift in patient profiles. The study, published in the nnals of Internal Medicine,xamined data from the Pennsylvania Department of Health, covering over 1.7 million cannabis certifications issued between November 2017 and December 2023.

Initially, chronic pain was the predominant justification for certification, accounting for approximately 67%, with PTSD at 16%. However, after anxiety was formally recognized, these figures declined to 41% for chronic pain and 11% for PTSD, while anxiety diagnoses surged to 60%, often listed alongside other conditions. This rapid increase indicates that expanding the list of qualifying conditions can significantly alter the composition of medical cannabis programs.

Despite these changes, the study noted that the overall size and participant behavior within the program remain unclear, especially regarding how many patients switched diagnoses or enrolled initially for anxiety. Experts from the research team pointed out that while cannabis has some evidence supporting its use for chronic pain, there is limited proof of its effectiveness for anxiety disorders. This raises concerns about patient perceptions and the potential for overestimating cannabis as a treatment for anxiety.

Dr. Coleman Drake emphasized the importance of filling research gaps to better understand cannabis's therapeutic roles, especially as market dynamics and usage patterns evolve. The study underscores the need for more rigorous scientific evidence to guide policy and clinical practice in medical cannabis use.

This development reflects a broader trend among states, with 39 currently having medical cannabis programs that historically prioritized conditions like chronic pain and PTSD. The inclusion of anxiety demonstrates a shift toward broader acceptance but also emphasizes the necessity for continued research to ensure safe and effective treatment options.

For more insights, read the full study: Link to study.

Source: https://medicalxpress.com/news/2025-07-medical-cannabis-drastically-adding-anxiety.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Addressing the Hidden Indoor Heat Risk: Urgent Need for Workplace Protections

A new report highlights the rising danger of indoor heat exposure among service sector workers, emphasizing the urgent need for updated workplace protections amidst rising temperatures and insufficient regulations.

Rizatriptan Ineffective Compared to Placebo in Early Treatment of Vestibular Migraine

A recent clinical trial reveals that rizatriptan is no more effective than placebo in alleviating vertigo and other vestibular migraine symptoms within the first hour, challenging its routine use for this condition.

New COVID Variant NB.1.8.1 Escalates Infections: What You Need to Know

A new COVID-19 variant, NB.1.8.1, is spreading globally and may affect infection rates. Learn about its origins, characteristics, symptoms, and what you can do to stay protected.